The American Journal of Surgery
Volume 193, Issue 5 , Pages 571-574 , May 2007

The impact of nodal isolated tumor cells on survival of breast cancer patients

Presented at the 93rd Annual Meeting of the North Pacific Surgical Association, Spokane, WA, November 10–11, 2006

Received 6 December 2006 ,Revised 29 January 2007

References 

  1. Fisher ER, Fisher B, Sass R, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol No. 4) (XI. Bilateral breast cancer). Cancer. 1984;54:3002–3011
  2. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864–1867
  3. Coombes RC, Berger U, Mansi J, et al. Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. NCI Monogr. 1986;1:51–53
  4. Susnik B, Frkovic-Grazio S, Bracko M. Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: a case-control study with 15-year follow-up. Ann Surg Oncol. 2004;11:568–572
  5. Cummings MC, Walsh MD, Hohn BG, et al. Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol. 2002;26:1286–1295
  6. Millis RR, Springall R, Lee AH, et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002;86:396–401
  7. Elson CE, Kufe D, Johnston WW. Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma (A study of 97 cases). Anal Quant Cytol Histol. 1993;15:171–178
  8. Dowlatshahi K, Fan M, Bloom KJ, et al. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer. 1999;86:990–996
  9. Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer. 1999;85:1098–1103
  10. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002;360:683–689
  11. Krauth JS, Charitansky H, Isaac S, et al. Clinical implications of axillary sentinel lymph node ’micrometastases’ in breast cancer. Eur J Surg Oncol. 2006;32:400–404
  12. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187
  13. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998;51:195–208
  14. Rosen PR, Groshen S, Saigo PE, et al. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol. 1989;7:355–366
  15. Lilleng PK, Hartveit F. ’Missed’ micrometastases—the extent of the problem. Acta Oncol. 2000;39:313–317
  16. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer. 1999;85:2183–2189
  17. Lundin J, Lundin M, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol. 2001;19:28–36
  18. Cote RJ, Peterson HF, Chaiwun B, et al. International Breast Cancer Study Group Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet. 1999;354:896–900

 This manuscript represents the opinions of the authors alone, and does not represent the views of the Department of Defense, the United States Army, or Madigan Army Medical Center.

PII: S0002-9610(07)00070-0

doi: 10.1016/j.amjsurg.2007.01.007

The American Journal of Surgery
Volume 193, Issue 5 , Pages 571-574 , May 2007

Article Tools

* Image Usage & Resolution